Active Pharmacovigilance in Peruvian Population: Surveillance of a Timolol/Brimonidine/Dorzolamide Ophthalmic Fixed Combination

References

• WHO. Pharmacovigilance: ensuring the safe use of medicines; Published 2004. Available from: https://apps.who.int/iris/bitstream/handle/10665/68782/WHO_EDM_2004.8.pdf;sequence=1. Accessed August 25, 2020
   Google Scholar
• Caster O, Juhlin K, Watson S, Norén GN. Improved statistical signal detection in pharmacovigilance by combining multiple strength-of-evidence aspects in vigiRank. Drug Saf. 2014;37(8):617–628. doi:10.1007/s40264-014-0204-5
   PubMed Web of Science ®Google Scholar
• Mann M, Mengistu A, Gaeseb J, et al. Active surveillance versus spontaneous reporting for first-line antiretroviral medicines in namibia: a cost–utility analysis. Drug Saf. 2016;39(9):859–872. doi:10.1007/s40264-016-0432-y
   Web of Science ®Google Scholar
• WHO. The importance of pharmacovigilance; Published 2002. Available from: https://apps.who.int/iris/handle/10665/42493. Accessed August 15, 2020
   Google Scholar
• Li X, Li H, Deng J, et al. Active pharmacovigilance in China: recent development and future perspectives. Eur J Clin Pharmacol. 2018;74(7):863–871. doi:10.1007/s00228-018-2455-z
   PubMed Web of Science ®Google Scholar
• Moses C, Celi LA, Marshall J. Pharmacovigilance: an active surveillance system to proactively identify risks for adverse events. Popul Health Manag. 2013;16(3):147–149. doi:10.1089/pop.2012.0100
   Web of Science ®Google Scholar
• Weinreb RN, Khaw PT. Primary open-angle glaucoma. Lancet. 2004;363(9422):1711–1720. doi:10.1016/S0140-6736(04)16257-0
   PubMed Web of Science ®Google Scholar
• Grzybowski A, Och M, Kanclerz P, Leffler C, De MCG. Primary open angle glaucoma and vascular risk factors: a review of population based studies from 1990 to 2019. J Clin Med. 2020;9:3. doi:10.3390/jcm9030761
   Web of Science ®Google Scholar
• Musch DC, Gillespie BW, Niziol LM, Lichter PR, Varma R. Intraocular pressure control and long-term visual field loss in the collaborative initial glaucoma treatment study. Ophthalmology. 2011;118(9):1766–1773. doi:10.1016/j.ophtha.2011.01.047
   PubMed Web of Science ®Google Scholar
• European glaucoma society. Terminology and guidelines for glaucoma, 4th edition – chapter 3: treatment principles and options supported by the EGS Foundation: part 1: foreword; introduction; glossary; chapter 3 treatment principles and options. Br J Ophthalmol. 2017;101(6):130–195.
   PubMed Web of Science ®Google Scholar
• Conlon R, Saheb H, Ahmed IIK. Glaucoma treatment trends: a review. Can J Ophthalmol. 2017;52(1):114–124.
   PubMed Web of Science ®Google Scholar
• Moshirfar M, Parker L, Birdsong OC, et al. Use of rho kinase inhibitors in ophthalmology: a review of the literature. Med Hypothesis, Discov Innov Ophthalmol J. 2018;7(3):101–111.
   PubMedGoogle Scholar
• Sharma S, Trikha S, Perera SA, Aung T. Clinical effectiveness of brinzolamide 1%-brimonidine 0.2% fixed combination for primary open-angle glaucoma and ocular hypertension. Clin Ophthalmol. 2015;9:2201–2207. doi:10.2147/OPTH.S72380
   PubMed Web of Science ®Google Scholar
• Sampaolesi R, Sampaolesi JR, Zárate J. The Glaucomas: Volume II – Open Angle Glaucoma and Angle Closure Glaucoma. 1st ed. Springer-Verlag Berlin Heidelberg; 2014.
   Google Scholar
• Hartwig SC, Siegel J, Schneider PJ. Preventability and severity assessment in reporting adverse drug reactions. Am J Hosp Pharm. 1992;49(9):2229–2232.
   PubMedGoogle Scholar
• Petrova G, Stoimenova A, Dimitrova M, Kamusheva M, Petrova D, Georgiev O. Assessment of the expectancy, seriousness and severity of adverse drug reactions reported for chronic obstructive pulmonary disease therapy. SAGE Open Med. 2017;5:2050312117690404. doi:10.1177/2050312117690404
   Web of Science ®Google Scholar
• Naranjo A, Busto U, Sellers E, et al. A method of estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239–245. doi:10.1038/clpt.1981.154
   PubMed Web of Science ®Google Scholar
• Timolol. Micromedex; Published 2020. Available from: https://www.micromedexsolutions.com/. Accessed September 25, 2020
   Google Scholar
• Brimonidine. Micromedex; Published 2020. Available from: https://www.micromedexsolutions.com/. Accessed August 15, 2020
   Google Scholar
• Dorzolamide. Micromedex; Published 2020. Available from: https://www.micromedexsolutions.com/. Accessed September 16, 2020
   Google Scholar
• Ciprofloxacin. Micromedex; Published 2020. Available from: https://www.micromedexsolutions.com/. Accessed August 20, 2020
   Google Scholar
• Mizranita V, Pratisto EH. Statin-associated ocular disorders: the FDA and ADRAC data. Int J Clin Pharm. 2015;37(5):844–850. doi:10.1007/s11096-015-0128-x
   Web of Science ®Google Scholar
• Fraunfelder FW, Richards AB. Diplopia, blepharoptosis, and ophthalmoplegia and 3-hydroxy-3-methyl-glutaryl-CoA reductase inhibitor use. Ophthalmology. 2008;115(12):2282–2285. doi:10.1016/j.ophtha.2008.08.006
   PubMed Web of Science ®Google Scholar
• Machan CM, Hrynchak PK, Irving EL. Age-related cataract is associated with type 2 diabetes and statin use. Optom Vis Sci off Publ Am Acad Optom. 2012;89(8):1165–1171. doi:10.1097/OPX.0b013e3182644cd1
   PubMed Web of Science ®Google Scholar
• Schlienger RG, Haefeli WE, Jick H, Meier CR. Risk of cataract in patients treated with statins. Arch Intern Med. 2001;161(16):2021–2026. doi:10.1001/archinte.161.16.2021
   Google Scholar
• Baiza-Durán LM, Llamas-Moreno JF, Ayala-Barajas C. Comparison of timolol 0.5% + brimonidine 0.2% + dorzolamide 2% versus timolol 0.5% + brimonidine 0.2% in a Mexican population with primary open-angle glaucoma or ocular hypertension. Clin Ophthalmol. 2012;6:1051–1055. doi:10.2147/OPTH.S33578
   PubMedGoogle Scholar
• The Royal Pharmaceutical Society. MARTINDALE drug reference; Published 2020. Available from: https://about.medicinescomplete.com/publication/martindale-the-complete-drug-reference/. Accessed May 4, 2020
   Google Scholar
• Gómez-Aguayo F, Paczka JA, Leñero-Córdova R, et al. A Phase III Randomized clinical trial of a 0.5% timolol + 0.2% brimonidine + 2.0% dorzolamide fixed combination, preservative-free ophthalmic solution vs. 0.5% timolol + 0.2% brimonidine + 2.0% dorzolamide fixed combination in patients with controlled pri. Ophthalmol Ther. 2018;7(1):145–156. doi:10.1007/s40123-018-0128-8
   PubMed Web of Science ®Google Scholar
• Barnebey HS, Robin AL. Adherence to fixed-combination versus unfixed travoprost 0.004%/timolol 0.5% for glaucoma or ocular hypertension: a randomized trial. Am J Ophthalmol. 2017;176:61–69. doi:10.1016/j.ajo.2016.12.002
   PubMed Web of Science ®Google Scholar
• Altafini R, Scherzer M-L, Hubatsch DA, Frezzotti P. Brinzolamide 1%/timolol versus dorzolamide 2%/timolol in the treatment of open-angle glaucoma or ocular hypertension: prospective randomized patient-preference study. Clin Ophthalmol. 2015;9:2263–2270. doi:10.2147/OPTH.S88891
   Google Scholar
• Lerner SF, Park KH, Hubatsch DA, Erichev V, Paczka JA, Roberts TV Efficacy and tolerability of travoprost 0.004%/timolol 0.5% fixed-dose combination for the treatment of primary open-angle glaucoma or ocular hypertension inadequately controlled with beta-blocker monotherapy. J Ophthalmol. 2017;2017:1917570. doi: 10.1155/2017/1917570
   PubMed Web of Science ®Google Scholar
• Hill AB. The environment and disease: association or causation? Proc R Soc Med. 1965;58(5):295–300.
   PubMedGoogle Scholar
• Bartlett JD. Ophthalmic Drug Facts. 25th Bartlett JD. Facts & Comparisons; 2013.
   Google Scholar